56541-14-1

Usage

Uses

Used in Pharmaceutical and Chemical Research:
N-CYCLOPROPYLTHIOUREA is utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows it to be a valuable component in drug development, contributing to the creation of novel therapeutic agents.
Used in Pesticide, Herbicide, and Fungicide Production:
N-CYCLOPROPYLTHIOUREA also plays a crucial role as an intermediate in the production of agricultural chemicals, such as pesticides, herbicides, and fungicides. Its inclusion in these products helps to enhance their effectiveness in controlling pests and diseases that affect crops.
Used in Organic Synthesis and Materials Science:
Due to its reactivity and distinctive chemical properties, N-CYCLOPROPYLTHIOUREA has potential applications in the broader field of organic synthesis. It can be employed to create new materials with specific properties for use in various industries, including but not limited to pharmaceuticals, agriculture, and materials science.

InChI:InChI=1/C4H8N2S/c5-4(7)6-3-1-2-3/h3H,1-2H2,(H3,5,6,7)

Upstream product

• 56541-16-3 N-cyclopropyl-N'-benzoylthiourea 
• 56601-42-4 cyclopropyl isothiocyanate 
• 333-20-0 potassium thioacyanate 
• 765-30-0 Cyclopropylamine 
• 1158178-29-0 triethylammonium cyclopropyldithiocarbamate 

Downstream Products

• 1160623-50-6 N-(3-(5-(2-chloro-4-pyrimidinyl)-2-(cyclopropylamino)-1,3-thiazol-4-yl)phenyl)-2,6-difluorobenzamide 
• 1229383-84-9 4-(2-bromophenyl)-N-cyclopropylthiazol-2-amine 
• 860344-66-7 4-(2-cyclopropylamino-thiazol-4-yl)-benzoic acid 
• 1126430-48-5 4-[3,5-bis(methyloxy)phenyl]-5-(2-chloro-4-pyrimidinyl)-N-cyclopropyl-1,3-thiazol-2-amine 
• 1126431-34-2 4-[4-chloro-3-(methyloxy)phenyl]-5-(2-chloro-4-pyrimidinyl)-N-cyclopropyl-1,3-thiazol-2-amine 

Relevant academic research and scientific papers

COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALARIA

The present invention provides aminohydantoin anti-malarial agents. In some embodiments, these agents have the property of functions of targeting malarial aspartic proteases while at the same time having low activity against human BACE. Methods of employing such agents are also provided.

GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein X1, X2, W, R1 to R5, L and m have the meaning according to the claims, are glucosidase inhibitors, and can be employed, inter alia, for the treatment of Alzheimer's disease.

NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS

The present invention is directed to novel compounds of formula (I) and their use in treating metabolic diseases.

THIAZOLE AND OXAZOLE KINASE INHIBITORS

The present invention provides thiazole and oxazole compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

An efficient synthesis of cyanamide from amine promoted by a hypervalent iodine(III) reagent

In a one-pot strategy we have achieved an efficient method for the synthesis of organic cyanamides starting from dithiocarbamic acid salts/amines. In this strategy the in situ generated alkyl or aryl isothiocyanates, obtained by the desulfurization of dithiocarbamic acid salts with diacetoxyiodobenzene (DIB) react with aqueous ammonia forming alkyl or aryl thiourea which on subsequent oxidative desulfurization with DIB led to the formation of corresponding cyanamide in good yields. Mild reaction conditions, shorter reaction time, an environmentally benign protocol, and easy isolation of the desired product make the present methodology a suitable alternative for the preparation of various organic cyanamides.

SUBSTITUTED N-ALKYLPYRIMIDINONES

This invention is directed generally to substituted pyrimidinone compounds that generally inhibit p38 kinase, TNF, and/or cyclooxygenase activity. Such substituted pyrimidinone include compounds generally corresponding in structure to the following formula (I): wherein R1, R2, R3, R4A, R4B, R4C, R4D and R4E are as defined in this specification. This invention also is directed to compositions of such substituted pyrimidinones (particularly pharmaceutical compositions), intermediates for the syntheses of such substituted pyrimidinones, methods for making such substituted pyrimidinones, and methods for treating (including preventing) conditions (typically pathological conditions) associated with p38 kinase activity, TNF activity, and/or cyclooxygenase-2 activity.

CYSTEINE PROTEASE INHIBITORS

A compound of the formula (II) wherein one of R1 and R2 is halo and the other is H or halo; R3 is C1-C4 straight or branched chain, optionally fluorinated, alkyl; R4 is H; or R3 together with R4 and the adjoining backbone carbon defines: a spiro-C5-C7 cycloalkyl, optionally substituted with 1 to 3 substituents selected from halo, hydroxyl, C1-C4 alkyl or C1-C4 haloalkyl; or optionally bridged with a methylene group; or a C4-C6 saturated heterocycle having a hetero atom selected from O, NRa, S, S(=O)2 ; where Ra is H, C1-C4 alkyl or CH3C(=O); R5 is independently selected from H or methyl; E is -C(=O)-, -S(=O)m-, -NR5S(=O)m-, -NR5C(=O)-, -OC(=O)-, R6 is a stable, optionally substituted, monocyclic or bicyclic, carbocycle or hetorocycle; m is independently 0,1 or 2; are inhibitors of cathepsin K and useful in the treatment or prophylaxis of osteoporosis.

THIAZOLE DERIVATIVES AND USE THEREOF

The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.